{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:50Z","timestamp":1792787930273,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"MSD China","id":[{"id":"https:\/\/ror.org\/01hr8kn45","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-05131-7","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:44:56Z","timestamp":1784335496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world study of posaconazole tablets for the prophylaxis of invasive fungal disease in patients with end-stage liver disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Yunru","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"issue":"3","key":"5131_CR1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s12072-023-10637-3","volume":"18","author":"T Chen","year":"2024","unstructured":"Chen T, Chen G, Wang GQ, Treeprasertsuk S, Lesmana CRA, Lin HC, et al. Expert consensus on the diagnosis and treatment of end-stage liver disease complicated by infections. Hepatol Int. 2024;18(3):817\u201332. https:\/\/doi.org\/10.1007\/s12072-023-10637-3.","journal-title":"Hepatol Int"},{"issue":"1","key":"5131_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3760\/cma.j.issn.1007-3418.2018.01.005","volume":"26","author":"L Zhang","year":"2018","unstructured":"Zhang L, Liu ZY. End-stage liver disease and invasive fungal infection. Zhonghua Gan Zang Bing Za Zhi. 2018;26(1):13\u20136. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2018.01.005.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"2","key":"5131_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3760\/cma.j.cn501113-20220130-00053","volume":"30","author":"[Consensus on","year":"2022","unstructured":"Consensus on. diagnosis and treatment of invasive fungal infection in patients with severe liver disease. Zhonghua Gan Zang Bing Za Zhi. 2022;30(2):159\u201368. https:\/\/doi.org\/10.3760\/cma.j.cn501113-20220130-00053.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"5131_CR4","unstructured":"Tao -Y, HuiFen -W, HaiBin -S, Fang -L, HaiMiao -X, Hong -Z et al. - Clinical study of factors in predicting prognosis of patients with hepatic failure after invasive fungal infections. J Clin Hep. 2009;25(2):110."},{"issue":"4","key":"5131_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/myc.12044","volume":"56","author":"LN Lin","year":"2013","unstructured":"Lin LN, Zhu Y, Che FB, Gu JL, Chen JH. Invasive fungal infections secondary to acute-on-chronic liver failure: a retrospective study. Mycoses. 2013;56(4):429\u201333. https:\/\/doi.org\/10.1111\/myc.12044.","journal-title":"Mycoses"},{"issue":"8","key":"5131_CR6","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1128\/aac.00222-12","volume":"56","author":"G Krishna","year":"2012","unstructured":"Krishna G, Ma L, Martinho M, O\u2019Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012;56(8):4196\u2013201. https:\/\/doi.org\/10.1128\/aac.00222-12.","journal-title":"Antimicrob Agents Chemother"},{"key":"5131_CR7","doi-asserted-by":"publisher","unstructured":"Guidelines for the diagnosis and treatment of acute-on-chronic liver failure. (2025 version). Zhonghua Gan Zang Bing Za Zhi 2025; 33 (4): 329\u2013339. https:\/\/doi.org\/10.3760\/cma.j.cn501113-20250312-00089.","DOI":"10.3760\/cma.j.cn501113-20250312-00089"},{"issue":"1","key":"5131_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12879-018-3055-3","volume":"18","author":"L Chen","year":"2018","unstructured":"Chen L, Wang Y, Zhang T, Li Y, Meng T, Liu L, et al. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis. BMC Infect Dis. 2018;18(1):155. https:\/\/doi.org\/10.1186\/s12879-018-3055-3.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"5131_CR9","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/jac\/dkx263","volume":"72","author":"OA Cornely","year":"2017","unstructured":"Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, et al. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017;72(12):3406\u201313. https:\/\/doi.org\/10.1093\/jac\/dkx263.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"5131_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367\u201376. https:\/\/doi.org\/10.1093\/cid\/ciz1008.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"5131_CR11","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1053\/j.gastro.2021.08.050","volume":"161","author":"WR Kim","year":"2021","unstructured":"Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021;161(6):1887\u2013e18951884. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.050.","journal-title":"Gastroenterology"},{"issue":"1","key":"5131_CR12","doi-asserted-by":"publisher","first-page":"Hep47","DOI":"10.2217\/hep-2023-0002","volume":"10","author":"A Aly","year":"2023","unstructured":"Aly A, Fulcher N, Seal B, Pham T, Wang Y, Paulson S, et al. Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology setting. Hepat Oncol. 2023;10(1):Hep47. https:\/\/doi.org\/10.2217\/hep-2023-0002.","journal-title":"Hepat Oncol"},{"issue":"12","key":"5131_CR13","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1128\/AAC.00022-10","volume":"54","author":"B Rochat","year":"2010","unstructured":"Rochat B, Pascual A, Pesse B, Lamoth F, Sanglard D, Decosterd LA, et al. Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing. Antimicrob Agents Chemother. 2010;54(12):5074\u201381. https:\/\/doi.org\/10.1128\/AAC.00022-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"5131_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/myc.13403","volume":"65","author":"T Lahmer","year":"2022","unstructured":"Lahmer T, Pe\u00e7anha-Pietrobom PM, Schmid RM, Colombo AL. Invasive fungal infections in acute and chronic liver impairment: A systematic review. Mycoses. 2022;65(2):140\u201351. https:\/\/doi.org\/10.1111\/myc.13403.","journal-title":"Mycoses"},{"issue":"1","key":"5131_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007990903364657","volume":"26","author":"A Moton","year":"2010","unstructured":"Moton A, Krishna G, Ma L, O\u2019Mara E, Prasad P, McLeod J, et al. Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment. Curr Med Res Opin. 2010;26(1):1\u20137. https:\/\/doi.org\/10.1185\/03007990903364657.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"5131_CR16","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1007\/s12325-020-01341-x","volume":"37","author":"K Liu","year":"2020","unstructured":"Liu K, Wu D, Li J, Chen H, Ning H, Zhao T, et al. Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection. Adv Therapy. 2020;37(5):2493\u2013506. https:\/\/doi.org\/10.1007\/s12325-020-01341-x.","journal-title":"Adv Therapy"},{"key":"5131_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","volume":"10","author":"BGJ Dekkers","year":"2016","unstructured":"Dekkers BGJ, Bakker M, van der Elst KCM, Sturkenboom MGG, Veringa A, Span LFR, et al. Therapeutic Drug Monitoring of Posaconazole: an Update. Curr Fungal Infect Rep. 2016;10:51\u201361. https:\/\/doi.org\/10.1007\/s12281-016-0255-4.","journal-title":"Curr Fungal Infect Rep"},{"issue":"3","key":"5131_CR18","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/jac\/dkv380","volume":"71","author":"OA Cornely","year":"2016","unstructured":"Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jim\u00e9nez JL, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2016;71(3):718\u201326. https:\/\/doi.org\/10.1093\/jac\/dkv380.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"5131_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","volume":"80","author":"L Chen","year":"2020","unstructured":"Chen L, Krekels EHJ, Verweij PE, Buil JB, Knibbe CAJ, Br\u00fcggemann RJM. Pharmacokinetics and Pharmacodynamics of Posaconazole. Drugs. 2020;80(7):671\u201395. https:\/\/doi.org\/10.1007\/s40265-020-01306-y.","journal-title":"Drugs"},{"key":"5131_CR20","doi-asserted-by":"publisher","first-page":"997018","DOI":"10.3389\/fcimb.2022.997018","volume":"12","author":"J Fang","year":"2022","unstructured":"Fang J, Yu CH, Li XJ, Yao JM, Fang ZY, Yoon SH, et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol. 2022;12:997018. https:\/\/doi.org\/10.3389\/fcimb.2022.997018.","journal-title":"Front Cell Infect Microbiol"},{"key":"5131_CR21","doi-asserted-by":"publisher","first-page":"575463","DOI":"10.3389\/fphar.2020.575463","volume":"11","author":"MM Jia","year":"2020","unstructured":"Jia MM, Zhang QW, Qin ZF, Lu RQ, Tian XK, Yang J, et al. Deciphering the Relationship Between the Trough Concentration of Posaconazole and Its Efficacy and Safety in Chinese Patients With Hematological Disorders. Front Pharmacol. 2020;11:575463. https:\/\/doi.org\/10.3389\/fphar.2020.575463.","journal-title":"Front Pharmacol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05131-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:39:53Z","timestamp":1791995993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05131-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5131"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05131-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of The First Affiliated Hospital of Xi\u2019an Jiaotong University (Approval No. XJTU1AF2019LSK-071) and was conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the Declaration of Helsinki (as revised in 2013). Written informed consent was obtained from all participants prior to study inclusion. For participants under the age of 16 years, written informed consent to participate was obtained from their parents or legal guardians. All study procedures, including the intervention, data analysis, and blood sample collection, were performed after informed consent had been obtained.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"646"}}